Liu Zhixian, Li Mengyuan, Jiang Zehang, Wang Xiaosheng
Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
School of Science, China Pharmaceutical University, Nanjing 211198, China.
Transl Oncol. 2018 Apr;11(2):311-329. doi: 10.1016/j.tranon.2018.01.011. Epub 2018 Feb 4.
Triple-negative breast cancer (TNBC) is a high-risk malignancy due to its high capacity for invasion and lack of targeted therapy. Immunotherapy continues to demonstrate efficacy in a variety of cancers, and thus may be a promising strategy for TNBC given the limited therapeutic options currently available for TNBC. In this study, we performed an exhaustive analysis of immunogenic signatures in TNBC based on 2 large-scale breast cancer (BC) genomic data. We compared enrichment levels of 26 immune cell activities and pathways among TNBC, non-TNBC, and normal tissue, and within TNBCs of different genotypic or phenotypic features. We found that almost all analyzed immune activities and pathways had significantly higher enrichment levels in TNBC than non-TNBC. Elevated enrichment of these immune activities and pathways was likely to be associated with better survival prognosis in TNBC. This study demonstrated that TNBC likely exhibits the strongest immunogenicity among BC subtypes, and thus warrants the immunotherapeutic option for TNBC.
三阴性乳腺癌（TNBC）因其高侵袭性和缺乏靶向治疗而成为一种高风险恶性肿瘤。免疫疗法在多种癌症中持续显示出疗效，鉴于目前TNBC的治疗选择有限，免疫疗法可能是TNBC的一种有前景的策略。在本研究中，我们基于2个大规模乳腺癌（BC）基因组数据对TNBC中的免疫原性特征进行了详尽分析。我们比较了TNBC、非TNBC和正常组织之间以及不同基因型或表型特征的TNBC内26种免疫细胞活性和通路的富集水平。我们发现，几乎所有分析的免疫活性和通路在TNBC中的富集水平都显著高于非TNBC。这些免疫活性和通路的富集升高可能与TNBC更好的生存预后相关。本研究表明，TNBC可能在BC亚型中表现出最强的免疫原性，因此TNBC值得采用免疫治疗方案。
